Management reduced full-year 2026 sales guidance to approximately $3.5 billion.
Wellspect Healthcare revenue grew 10% year over year to $92 million.
Clinical education investments in North America increased sixfold year over year.
On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Dentsply Sirona (NASDAQ:XRAY) announced lower full-year net sales and earnings guidance. Revenue fell 7.6% as reported, driven by weakness across dental equipment lines. Long-term investors must weigh these operational headwinds against ongoing investments in commercial sales teams and product innovation.
Three things management said stand out.
Management lowered its net sales expectations to approximately $3.5 billion and reduced adjusted earnings per share, a key profitability metric, to between $1.20 to $1.30. Higher distribution costs and weaker equipment demand created headwind pressures that extra cost cuts didn't fully offset.
We now expect full-year net sales of approximately $3.5 billion versus the range of $3.5 billion-$3.6 billion previously, and adjusted EPS of $1.20-$1.30 from $1.40-$1.50, excluding the $0.17 one-time gain from tariff refunds.
-- Dan Scavilla, President and Chief Executive Officer
Management multiplied its spending on clinical training programs in North America to build practitioner loyalty and drive usage across its endodontic, or root canal treatment, product line. This commercial strategy prioritizes product adoption over short-term operating margin expansion.
Our second half 2026 clinical education investment in North America is six times greater than last year's level, including more than 160 endo courses and expanded hands-on programs.
-- Dan Scavilla, President and Chief Executive Officer
The Wellspect Healthcare business, which produces continent urinary catheter products, delivered 10% revenue growth during the quarter to reach $92 million. Focused commercial spending expanded the division's reach in the $7 billion market.
Investments in new products and U.S. commercial capabilities are supporting broader market reach and continued growth.
-- Dan Scavilla, President and Chief Executive Officer
Green shoots in U.S. dental implants and restorative lines signal initial operational progress, and leadership is pushing to convert these early gains into sustainable organic momentum. The business continues building out dedicated teams for dental support organizations, which are corporate dental practice chains, while sharpening research and development discipline. Management is tracking distributor inventory levels, sales force vacancy rates, and pricing discipline to evaluate progress.
The task is now to extend that progress across the portfolio and deliver more consistent results.
-- Dan Scavilla, President and Chief Executive Officer
Stabilizing core equipment sales while maintaining cost control remains central to deleveraging, which means paying down debt to improve financial flexibility. Capital allocation priorities lean heavily toward debt reduction alongside disciplined reinvestment in commercial execution.
My priorities are to translate these capabilities into more consistent execution, disciplined investment, and stronger cash generation.
-- John Fortson, Executive Vice President and Chief Financial Officer
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.